ROIV Stock Summary and Trading Ideas (Roivant Sciences Ltd. - Common Shares | NASDAQ:ROIV)

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Ltd. - Common Shares trades on the NASDAQ stock market under the symbol ROIV.

As of April 2, 2026, ROIV stock price climbed to $28.33 with 4,684,285 million shares trading.

ROIV has a beta of 0.82, meaning it tends to be less sensitive to market movements. ROIV has a correlation of 0.18 to the broad based SPY ETF.

ROIV has a market cap of $20.28 billion. This is considered a Large Cap stock.

Last quarter Roivant Sciences Ltd. - Common Shares reported $2 million in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.10.

In the last 3 years, ROIV traded as high as $30.33 and as low as $6.97.

The top ETF exchange traded funds that ROIV belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.

ROIV has outperformed the market in the last year with a price return of +187.6% while the SPY ETF gained +18.2%. ROIV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +30.6% and +1.9%, respectively, while the SPY returned -3.6% and -0.6%, respectively.

ROIV support price is $27.19 and resistance is $28.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ROIV shares will trade within this expected range on the day.